Press release archive - GSK
GSK announces headline results from the FIRST-ENGOT-OV44 phase III trial. Regulatory designation based on promising preliminary clinical data. Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab.
Press releases | GSK US
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines. Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. Studies from OPERA and Trio cohorts provide further real-world evidence.
Next stage in GSK’s Zantac defense gets underway today
1 day ago · GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. In the age of AI,...
GSK Nears $1 Billion Deal for Biotech Company IDRx - BNN …
2 days ago · Signage at a GlaxoSmithKline facility in Rockville, Maryland, US, on Monday, Aug. 26, 2024. The US Food and Drug Administration has granted Breakthrough Therapy Designation for GSK'227, an investigational B7-H3-targeted antibody drug conjugate being evaluated for the treatment of patients with extensive-stage small-cell lung cancer, according to astatement.
GlaxoSmithKline News | GSK News - NewsNow
NewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications.
GSK announces cap of $35 per month on U.S. patient out-of …
GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory medici...
GSK plans phase 3 for hepatitis B drug bepirovirsen, despite …
2 days ago · GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”
GlaxoSmithKline | AP News
Dec 19, 2018 · A research scientist from California pleaded guilty Friday in Philadelphia federal court to receiving trade secrets on anticancer research smuggled from pharmaceutical giant GlaxoSmithKline to bolster a fledgling but potential rival startup in China.
GlaxoSmithKline Latest News & Analysis - BBC
Jan 17, 2022 · GlaxoSmithKline rejected three offers, saying they "undervalued" its consumer goods business. GSK aims to expand its Stevenage facility to create one of the largest life …